» Articles » PMID: 16150825

Lipoprotein [a] is Cleared from the Plasma Primarily by the Liver in a Process Mediated by Apolipoprotein [a]

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2005 Sep 10
PMID 16150825
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The cellular and molecular mechanisms responsible for lipoprotein [a] (Lp[a]) catabolism are unknown. We examined the plasma clearance of Lp[a] and LDL in mice using lipoproteins isolated from human plasma coupled to radiolabeled tyramine cellobiose. Lipoproteins were injected into wild-type, LDL receptor-deficient (Ldlr-/-), and apolipoprotein E-deficient (Apoe-/-) mice. The fractional catabolic rate of LDL was greatly slowed in Ldlr-/- mice and greatly accelerated in Apoe-/- mice compared with wild-type mice. In contrast, the plasma clearance of Lp[a] in Ldlr-/- mice was similar to that in wild-type mice and was only slightly accelerated in Apoe-/- mice. Hepatic uptake of Lp[a] in wild-type mice was 34.6% of the injected dose over a 24 h period. The kidney accounted for only a small fraction of tissue uptake (1.3%). To test whether apolipoprotein [a] (apo[a]) mediates the clearance of Lp[a] from plasma, we coinjected excess apo[a] with labeled Lp[a]. Apo[a] acted as a potent inhibitor of Lp[a] plasma clearance. Asialofetuin, a ligand of the asialoglycoprotein receptor, did not inhibit Lp[a] clearance. In summary, the liver is the major organ accounting for the clearance of Lp[a] in mice, with the LDL receptor and apolipoprotein E having no major roles. Our studies indicate that apo[a] is the primary ligand that mediates Lp[a] uptake and plasma clearance.

Citing Articles

Lipoprotein(a) and cardiovascular disease.

Boffa M, Koschinsky M Biochem J. 2024; 481(19):1277-1296.

PMID: 39302109 PMC: 11555715. DOI: 10.1042/BCJ20240037.


Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening.

Khan T, Bragazzi Cunha J, Raut C, Burroughs M, Goonewardena S, Smrcka A bioRxiv. 2024; .

PMID: 38766193 PMC: 11100788. DOI: 10.1101/2024.05.11.593568.


Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview.

Suh S, Kim S Diabetes Metab J. 2023; 47(5):612-629.

PMID: 37482655 PMC: 10555535. DOI: 10.4093/dmj.2023.0067.


Serum Lipoprotein(a) and High-Density Lipoprotein Cholesterol Associate with Diabetic Nephropathy: Evidence from Machine Learning Perspectives.

Gao R, Liu B, Yang Y, Ran R, Zhou Y, Liu S Diabetes Metab Syndr Obes. 2023; 16:1847-1858.

PMID: 37378072 PMC: 10292662. DOI: 10.2147/DMSO.S409410.


Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option.

Maloberti A, Fabbri S, Colombo V, Gualini E, Monticelli M, Daus F Int J Mol Sci. 2023; 24(1).

PMID: 36613613 PMC: 9820656. DOI: 10.3390/ijms24010170.